Skip to main content
Caplight Logo









Apeikon Therapeutics

Apeikon Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.apeikon.co.uk/

Last Round

Seed

Mar 31, 2023

Total Funding Raised

$1.37M

Company Overview

Apeikon Therapeutics is a biotechnology company that develops image-guided, activatable nanoparticle technology for the targeted delivery of anti-cancer drugs to tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical Devices, Medical Imaging

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted drug deliverynanoparticle technologymagnetic resonance-guided focused ultrasoundMRgFUSprecision medicinedrug delivery platformtheranosticsliposomal drug deliveryimage-guided therapyoncology biotechsmart drug deliverysolid tumor treatmentbiotech spin-outpre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apeikon Therapeutics Comparables

Compare Apeikon Therapeutics with similar companies based on industry and business-model similarity.

Apeikon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Advanced Microbubbles, Inc.
77%
OxSonics Therapeutics
77%
Exact Therapeutics AS
76%

Apeikon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 31, 2023
AngelNov 30, 2022
GrantMar 1, 2022

Apeikon Therapeutics Investors

Notable investors and investment history

Apeikon Therapeutics investors
InvestorRounds
Innovate UKGrant
SFC CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 30, 2022

    King's College London participated in the round.

  • Mar 1, 2022

    $1.19M grant awarded by Innovate UK

Apeikon Therapeutics Filings

Explore SEC and related filing metadata, where available.

Apeikon Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Apeikon Therapeutics's valuation, stock price, and market status.

Is Apeikon Therapeutics a public or private company?

Apeikon Therapeutics is a private company.

What is the current stock price of Apeikon Therapeutics?

Apeikon Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Apeikon Therapeutics worth (valuation)?

Valuation information for Apeikon Therapeutics is not publicly available.

Can I buy Apeikon Therapeutics stock?

Apeikon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Apeikon Therapeutics's last funding round?

Apeikon Therapeutics's most recent funding round was Seed on March 31, 2023.

Who are the main investors in Apeikon Therapeutics?

Key investors in Apeikon Therapeutics include Innovate UK, SFC Capital.

Will Apeikon Therapeutics IPO soon?

No public IPO plans have been announced for Apeikon Therapeutics.

How can I track Apeikon Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Apeikon Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range2
Year Founded2020
Last FundingMar 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?